Dendreon Corp. (DNDN)
-NasdaqGS 3.95 
0.01(0.25%) May 22, 4:00PM EDT|After Hours
:
3.93 0.02 (0.51%) May 22, 6:50PM EDT
| Prev Close: | 3.96 |
|---|
| Open: | 3.99 |
|---|
| Bid: | 3.90 x 100 |
|---|
| Ask: | 4.00 x 1200 |
|---|
| 1y Target Est: | 4.98 |
|---|
| Beta: | 2.81 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 3.92 - 4.04 |
|---|
| 52wk Range: | 3.69 - 7.94 |
|---|
| Volume: | 2,667,355 |
|---|
| Avg Vol (3m): | 4,526,490 |
|---|
| Market Cap: | 601.31M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.42 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Biotech Investing for Beginnersat Motley Fool(Wed, May 22)
- Dendreon Analysts Getting Very Skepticalat Seeking Alpha(Wed, May 22)
- Bayer's Xofigo Cleared in the USZacks(Thu, May 16)
- One Person's Trash Is Another Person's Treasure Portfolioat Motley Fool(Thu, May 16)
- DENDREON CORP FinancialsEDGAR Online Financials(Wed, May 15)
- Bayer, Algeta Win U.S. Approval for Prostate Cancer Drugat Bloomberg(Wed, May 15)
- Today's Market News To Trade On: 5 Stocks Moving On Newsat Seeking Alpha(Wed, May 15)
- Dendreon's Management Presents at Bank of America Merrill Lynch 2013 Health Care Conference (Transcript)at Seeking Alpha(Tue, May 14)
- Once Heralded Dendreon May Be Approaching The End Of Its Financial Roadat Seeking Alpha(Tue, May 14)
- Does Dendreon Still Have Potential?at Wall St. Cheat Sheet(Tue, May 14)
- Three of WellPoint's directors resign for personal reasonsat Reuters(Mon, May 13)
- 2 Scenarios Where Buy and Hold Rarely Worksat Motley Fool(Mon, May 13)
- Position Yourself For Big Returns In The Stem Cell Space: Jason Kolbertat Seeking Alpha(Mon, May 13)
- SmithOnStocks Opines On Recent Biotech Newsat Seeking Alpha(Mon, May 13)
- 5 of Last Week's Biggest Losersat Motley Fool(Sun, May 12)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 1.94 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.55 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.42 |
|---|
| Mean Recommendation*: | 3.4 |
|---|
| PEG Ratio (5 yr expected): | -0.03 |
|---|
Business Summary
Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients.
View More